Mergers, Acquisitions and Joint Ventures
Sanofi acquires Protein Sciences (Meriden, Connecticut, USA), a privately held vaccines biotechnology company, for $650 million, and will make an additional $100 million payment upon achievement of certain milestones. Protein Sciences platform is based on a recombinant insect virus-based expression technology, which was used to produce Flubok, the only recombinant protein-based influenza bases vaccine approved by the US FDA. Protein Sciences employs a Baculovirus Expression Vector Syste (BEVS) to optimize its proprietaty Spodoptera frugiperda insect cell line, express SF+ cells. The reengineered high-density and serum-free cell line generates quantities of the desired recombinant vaccine much faster than using egg-based platform. Under the terms of the deal, Sanofi will also get access to Protein Sciences manufacturing facility in Pearl River (NY, USA), with a 2,000L bioreactor, acquired from Pfizer in 2012 and repurposed to produce Flubok.
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.